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Abstract
Background: Lymph node metastasis constitutes a key event in tumor progression. The molecular control of this
process is poorly understood. Heparan sulfate is a linear polysaccharide consisting of unique sulfate-modified
disaccharide repeats that allow the glycan to bind a variety of proteins, including chemokines. While some
chemokines may drive lymphatic trafficking of tumor cells, the functional and genetic importance of heparan
sulfate as a possible mediator of chemokine actions in lymphatic metastasis has not been reported.
Results: We applied a loss-of-function genetic approach employing lymphatic endothelial conditional mutations in
heparan sulfate biosynthesis to study the effects on tumor-lymphatic trafficking and lymph node metastasis.
Lymphatic endothelial deficiency in N-deacetylase/N-sulfotransferase-1 (Ndst1), a key enzyme involved in sulfating
nascent heparan sulfate chains, resulted in altered lymph node metastasis in tumor-bearing gene targeted mice.
This occurred in mice harboring either a pan-endothelial Ndst1 mutation or an inducible lymphatic-endothelial
specific mutation in Ndst1. In addition to a marked reduction in tumor metastases to the regional lymph nodes in
mutant mice, specific immuno-localization of CCL21, a heparin-binding chemokine known to regulate leukocyte
and possibly tumor-cell traffic, showed a marked reduction in its ability to associate with tumor cells in mutant
lymph nodes. In vitro modified chemotaxis studies targeting heparan sulfate biosynthesis in lymphatic endothelial
cells revealed that heparan sulfate secreted by lymphatic endothelium is required for CCL21-dependent directional
migration of murine as well as human lung carcinoma cells toward the targeted lymphatic endothelium.
Lymphatic heparan sulfate was also required for binding of CCL21 to its receptor CCR7 on tumor cells as well as
the activation of migration signaling pathways in tumor cells exposed to lymphatic conditioned medium. Finally,
lymphatic cell-surface heparan sulfate facilitated receptor-dependent binding and concentration of CCL21 on the
lymphatic endothelium, thereby serving as a mechanism to generate lymphatic chemokine gradients.
Conclusions: This work demonstrates the genetic importance of host lymphatic heparan sulfate in mediating
chemokine dependent tumor-cell traffic in the lymphatic microenvironment. The impact on chemokine dependent
lymphatic metastasis may guide novel therapeutic strategies.
Background
Lymphatic metastasis in carcinoma is a major and early
step during tumor progression, and its presence is a key
determinant of cancer staging, treatment, and prognosis
[1-3]. The process is characterized by pathophysiologic
events that include local migration/invasion of tumor
into lymphatic vessels, transport and survival within the
lymphatic lumen, and colonization of regional lymph
nodes [4,5]. In cancer, lymphatic remodeling and tumor
invasion into the lymphatic conduit contribute directly
to lymph node metastasis [6,7], and tumor-derived
g r o w t hf a c t o r ss u c ha sV E G F - Ca sw e l la sc h e m o k i n e s
produced by lymphatic vessels, such as CCL21/SLC
(secondary lymphoid chemokine), have recently been
implicated as key mediators of such events [8,9]. Recent
studies have also shown that the chemokine receptor
CCR7, which regulates lymphatic trafficking of leuko-
cytes, including dendritic cells and T-cells, may contri-
bute to lymph node metastasis of various cancers
through interaction with its two known ligands, CCL21
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lymphatic endothelium, and known to drive lymphatic-
directed immune cell traffic [13,14], it has been
hypothesized that tumor cells may usurp this pathway
in order to drive lymphatic invasion by over-expressing
the CCR7 receptor [8,9,15]. The latter has been shown
to correlate with nodal metastasis in human neoplasia
[10,16,17]. More generally CCL21 may work in synergis-
tic and redundant manners with other chemokines pro-
duced by lymphatic endothelium to facilitate lymphatic
invasion by tumor cells that over-express chemokine
cognate receptors [15,18]. Herein, we report the discov-
ery of a central role played by unique glycans in regulat-
ing chemokine-mediated carcinoma cell traffic in vivo
and in vitro, and we focus on CCL21 as a prototypical
chemokine regulated by this novel process.
Recent studies have revealed a variety of co-receptor
molecules that may regulate the coordinated actions of
multiple lymphatic growth factors and/or chemokines
during tumor lymphatic progression and metastasis.
These include neuropilin-2 [19], integrins [20,21], and
proteoglycans. The latter comprise a broad and ubiqui-
tous class of glycoconjugates that play important roles
in matrix and vascular remodeling, including the pro-
gression of such events in neoplasia (reviewed in
[22,23]). By virtue of uniquely sulfated heparan sulfate
(HS) glycan chains tethered to HS proteoglycan core
proteins distributed over cell surfaces and the extracellu-
lar matrix (ECM), a variety of soluble proteins endowed
with basic amino acid-rich domains, including growth
factors and chemokines [24-26], may interact with nega-
tively charged sulfate motifs on HS so as to form spatial
gradients that may be biased by expression and distribu-
tion of the glycan. Heparan sulfate proteoglycans have
been identified on lymphatic vessels [27]; and some che-
mokines, such as CCL21 and CXCL12, have been found
to associate with both HS [28-30] as well as lymphatic
endothelium during inflammation [18,31]. In neoplasia,
HS may support chemokine gradients on the lymphatic
vessel surface and ECM; however, direct in vivo evi-
dence for this is lacking. Moreover, vascular chemokine
signaling, which is influenced by rapid wash-out of che-
mokine as a result of blood- (or lymph) flow [32], may
require matrix-associated HS to not only tether gradi-
ents of the relevant chemokines under flow, but also to
critically support chemokine clustering and oligomeriza-
tion required for optimal receptor binding and activa-
tion [26,32].
To examine the importance of the fine structure of HS
in mediating tumor cell traffic in the lymphatic microen-
vironment, we genetically targeted lymphatic HS bio-
synthesis, and examined the effects on tumor-lymphatic
chemo-attraction as well as lymph node trafficking
in gene-targeted mice. Heparan sulfate is a linear
polysaccharide that is covalently attached to either cell-
surface bound or secreted proteoglycan core proteins.
Structurally, HS is closely related to heparin, consisting of
repeated disaccharide units of alternating uronic acid
[D-glucuronic acid (GlcA) or L-iduronic acid (IdoA)] and
D-glucosamine (GlcN) units [33]. As a result of unique
modifications, including acetylation or sulfation on the
a m i n og r o u p ,O - s u l f a t i o na tt h e3 -a n d6 - p o s i t i o n so f
GlcN, epimerization of GlcA to IdoA, and 2-O-sulation
of IdoA, HS exhibits diverse structures with diverse func-
tions [33,34]. The fine structure is precisely regulated by
distinct chain-initiating enzymes (e.g., xylosyltransferase
[XylT], which initiates sugar assembly on proteoglycan
core proteins), polymerizing enzymes, and sulfate-modify-
ing enzymes. The latter include the N-deacetylase/
N-sulfotransferase (Ndst) family of isoenzymes, which
initiates sulfation of nascent HS chains at discrete sites
along the chain [22]. The sulfate modifications endow HS
with the ability to bind and regulate the actions of
growth factors as well as chemokines, such as interleukin
8 (IL-8) and stromal-derived factor-1a (CXCL12/SDF-
1a), among others [35]. While a few HS-chemokine bind-
ing interactions have been characterized, including
demonstration of altered heparin binding as a result of
targeting specific basic amino acid - rich protein domains
of certain chemokines [26], the biological importance of
targeting the presence or biosynthesis of the glycan in
chemokine-dependent tumor cell trafficking, including
lymph node metastasis, has never been reported.
In this study, we report that genetic alteration of lym-
phatic endothelial HS disrupts chemokine-dependent
migration of tumor cells toward the targeted endothe-
lium; and deletion of Ndst1 in the lymphatic endothelium
in vivo is sufficient to alter lymph node colonization by
tumor. In cell-based studies, we investigate mechanisms
that may underlie these findings, and show that CCL21-
dependent tumor cell migration toward lymphatic
endothelium critically depends upon lymphatic HS. We
demonstrate that targeted disruption of HS produced
into the conditioned medium of lymphatic endothelia is
sufficient to abrogate CCL21-CCR7 binding as well as
the activation of migration signaling pathways in tumor
cells exposed to the same medium. In addition, we show
that lymphatic cell-surface HS may serve as a source for
the establishment of CCL21 gradients that drive tumor
cell migration. These findings suggest key roles for lym-
phatic HS during the trafficking of tumor cells and colo-
nization of lymph nodes in carcinoma.
Results
Lymphatic endothelial HS is required for directional
invasion of tumor cells across matrix
To test whether HS produced by lymphatic endothelial
cells in collagen matrix plays a role in attracting the
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Page 2 of 20invasion of tumor cells in vitro, we designed a matrix-
based invasion assay: Primary human lymphatic
endothelial cells (hLEC) were embedded in type-I col-
lagen on the underside of transwell filters, and either
murine Lewis lung carcinoma cells (LLCs) stably expres-
sing GFP or human lung carcinoma (H1650) cells
labeled with fluorophore (calcein) were loaded on top of
the insert. Tumor cells were allowed to invade into the
collagen gel, and gel-incorporated tumor cells were
quantified in the setting of unique conditions targeting
HS produced by the hLEC (Figure 1). Two targeting
approaches were applied to target lymphatic endothelial
HS in the system: (1) Enzymatic pre-treatment of the
hLEC with heparinase (which destroys HS chains [36]),
and (2) altering HS production via pre-treatment of the
hLEC with siRNA targeting HS biosynthetic enzymes.
Transient transfection of the hLEC with siRNA resulted
in approximately 80% knockdown of targeted mRNAs,
and ~70% reduction at the protein level, as compared to
control transfection of hLEC with scrambled-duplex
RNA (siDS) (Additional File 1 - Figure S1).
The presence of control hLEC in the collagen was able
to drive invasion by LLCs (Figure 1B, compare invasion
toward “hLEC” control cells to that toward “NC” (no
hLEC) negative control)). The presence of blocking anti-
bodies to either CCL21 or CCR7 significantly reduced
invasion; and the presence of intact HS on the hLEC
was necessary for LLC invasion, as evidenced by marked
inhibition upon treating the hLEC with heparinase,
which destroys HS. Targeting the HS sulfating enzymes
Ndst1 or Hs2st (responsible for glucuronyl N-sulfation
or iduronyl 2-O-sulfation of HS, respectively), also sig-
nificantly reduced LLC invasion (Figure 1C). In contrast,
antibody blockade of CCL5 (Figure 1B) or treatment
with siRNA targeting a distinct HS sulfating enzyme (i.
e., Hs3st1 (Figure 1C) responsible for glucoronyl 3-O-
sulfation of HS) did not significantly inhibit invasion,
suggesting distinct and specific requirements with
r e s p e c tt oc h e m o k i n e sa sw e l la st h ef i n es t r u c t u r eo f
lymphatic endothelial HS in the system. Targeting lym-
phatic endothelial HS during invasion by human lung
adenocarcinoma (H1650) cells also abrogated the ability
of the tumor cells to invade (Figure 1D).
Genetic targeting of pan-endothelial HS biosynthesis
alters the spread of Lewis lung carcinoma to regional
lymph nodes
The initial in vitro findings prompted us to target lym-
phatic HS biosynthesis in vivo, and examine how that
might affect colonization of regional lymph nodes by
tumor cells. In a preliminary model, Lewis lung carci-
noma (LLC) cells (syngeneic on the C57Bl/6 back-
ground) were subcutaneously injected into the left
caudal/medial inguinal fold of Ndst1
f/fTekCre
+ mutant
mice (N = 8) and their Cre
- wildtype littermates (N = 6)
to induce tumors. Mutants have a pan-endothelial defi-
ciency in the major HS sulfating enzyme Ndst1 [37,38].
Knockdown was confirmed in primary lymphatic
Figure 1 Invasion of tumor cells toward matrix-embedded
lymphatic endothelial cells depends on lymphatic heparan
sulfate. A. Schematic representation of a modified transwell
collagen invasion assay. TC, tumor cells; hLEC, primay human lung
lymphatic endothelial cells; Col, type I collagen gel. B and C.
Invasion of Lewis lung carcinoma cells (LLC) toward collagen gel
containing either no cells ("NC”) or hLEC treated as indicated was
quantified and normalized to NC. aCCL21, aCCR7 or aCCL5,
blocking antibodies to CCL21, CCR7 or CCL5, respectively; H’ase,
hLEC pre-treated with heparinase; siDS, hLEC transfected with
control (scrambled duplex) RNA; siNdst1, siXylT2, siHs2st or siHs3st1,
hLEC transfected with siRNA targeting corresponding HS
biosynthetic enzymes. D. Invasion of human lung adenocarcinoma
cells (H1650) toward collagen gel containing either no cells ("NC”)
or hLEC treated as indicated was quantified and normalized to NC.
*P < 0.01,
#P < 0.05, as compared to hLEC in B and siDS in C and D.
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wildtype littermates, wherein deletion efficiency of the
loxP-flanked allele of Ndst1 in cultured primary LEC
from Cre
+ mutants was found to be ~75% by quantita-
tive genomic PCR, consistent with the known lymphatic
endothelial expression of the Tek promoter in vivo
[39,40]. When primary LLC tumor size reached ~0.5 cm
in diameter (where primary tumor size was comparable
among mutants and wildtype littermates), the regional
subiliac lymph node from each mouse was isolated, and
nodal tumor mestastasis was examined using pan-kera-
tin immunohistochemical (IHC) staining (Figure 2).
Colonization of lymph nodes by tumor in the mutants
was markedly reduced compared to that in Cre
- litter-
mates (comparing lymph node pan-keratin immunoreac-
tivity; Figure 2A), suggesting that appropriate sulfation
of lymphatic endothelial HS was essential for lymphatic
metastasis. With respect to CCL21: Lymph nodes from
wildtype mice that were not challenged with tumor
were characterized by minimal CCL21 immunoreactivity
distributed in the matrix surrounding LYVE-1-positive
lymphatic vessels (Figure 2B, top panels). In tumor-chal-
lenged wildtype littermates, large areas of CCL21 posi-
tive cells were detected throughout the lymph node
cortices, and pan-keratin positive patches of metastatic
tumor cells in the lymph nodes were co-localized with
CCL21 immunoreactivity (Figure 2B, middle row).
However, in Cre+ mutants, pan-keratin positive tumor
patches were markedly reduced (Figure 2A, graph and
photomicrographs), and detectable tumor deposits were
characterized by minimal associated CCL21 immunor-
eactivity (Figure 2B, bottom row). In the course of
LYVE-1 staining, we noted that the LLC primary tumor
was characterized by an absence of intra-tumoral
LYVE1-positive lymphatic vessels in wildtype mice; and
at the given primary tumor size (0.5 cm diameter), the
density of sparse lymphatic vessels along the periphery
of tumors from mutant versus wildtype littermates did
not significantly differ (data not shown).
Lymphatic endothelial conditioned medium is sufficient
to drive chemokine-dependent tumor cell migration, and
altering lymphatic HS in the medium disrupts migration
We next examined whether HS secreted by lymphatic
endothelial cells might facilitate chemokine-dependent
tumor cell migration toward lymphatic endothelium. To
study this, LLC tumor cells on the upper side of transwell
filters were separated from HS-targeted hLEC mono-
layers in the lower wells by liquid medium (Figure 3A),
and LLC migration into the bottom wells was quantified.
T h ep r e s e n c eo fh L E Ci nt h eb o t t o mw e l lw a ss u f f i c i e n t
to drive LLC migration (Figure 3B), and blocking either
Figure 2 Genetic targeting of pan-endothelial heparan sulfate biosynthesis impairs metastasis of carcinoma to regional lymph nodes.
LLC tumor cells were injected subcutaneously into the left caudal/medial inguinal region of Ndst1
f/fTekCre+ mutant mice, which bear a pan-
endothelial mutation in the major HS sulfating enzyme Ndst1, and their wildtype Cre- littermates as controls. After 14 days, the left subiliac
lymph node (draining the primary tumor) from each mouse was isolated. A. Metastaic tumor cells in the lymph nodes (LN) were detected using
anti-pan-keratin antibody (blue stain) on LN tissue sections imaged under 100× magnification, and quantified (NIH Image-J) to determine net
pixel intensity for each LN. Values were normalized to the mean pixel value/LN among control (Ndst1
f/fTekCre-) littermates. Graph is shown
below; *P = 0.016, for difference in mean values (red bars) for mutant (N = 8) vs control (N = 6) mice. B. Representative LN tissue sections from
tumor-bearing mutant (bottom row of photomicrographs) vs wildtype (Cre
-) controls (middle row) were co-stained with CCL21 (blue) and LYVE1
(brown) (left two panels) or pan-keratin (blue, right panel). The top row of photomicrographs shows a representative LN section from a non-
challenged (tumor free) control mouse. Scale bars, 100 μm for 100× and 50 μm for 400× magnification photomicrographs.
Yin et al. Molecular Cancer 2010, 9:316
http://www.molecular-cancer.com/content/9/1/316
Page 4 of 20Figure 3 Migration of Lewis lung carcinoma cells toward lymphatic endothelial cells depends on lymphatic heparan sulfate. A.
Schematic representation of a modified transwell chemotaxis assay, wherein liquid medium separates migrating LLC tumor cells that initiate in
the upper well and migrate toward lower wells that contain either no cells or hLEC monolayers treated under various conditions. B and C.
Transwell migration of tumor cells into lower wells plated with either no cells as a negative control ("NC”) or hLEC monolayers treated as
indicated was quantified, and plotted for each condition as the mean -fold response over the value for NC (and normalized to the NC value).
Conditions in B refer to the addition of specific blocking antibodies or pre-treatment of the hLEC with heparinase (H’ase); and conditions in C
refer to treatment of the hLEC with siRNA targeting the indicated HS biosynthetic enzymes. *P < 0.01,
#P < 0.05, as compared to hLEC group in
B and siDS group in C. D. Graphs quantifying transwell migration of either LLC (upper graph) or H1650 (lower graph) lung carcinoma cells into
lower wells plated with either no cells (NC), control hLEC (siDS), or siXylT2 targeted hLEC. The condition “siXylT2+HS” (far right) refers to addition
of heparan sulfate purified from cultured control hLEC into the lower-well medium during tumor cell migration toward siXylT2 targeted hLEC.
Fractions (0.04 and 0.2) of the total HS needed for rescue were used in separate wells to test dose-response.
#P < 0.05, *P < 0.01, **P < 0.001 for
histogram comparisons indicated by horizontal bars.
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synthesis of hLEC HS (Figure 3C; using siRNA targeting
XylT2, Ndst1, or Hs2st) significantly reduced LLC migra-
tion. In contrast, CCL5 blocking antibody (Figure 3B) or
treatment of hLEC with Hs3st1 siRNA (Figure 3C) was
not sufficient to alter migration, suggesting that the pre-
sence- as well as specific sulfation properties of HS pro-
duced in the hLEC conditioned medium is required for
chemokine-dependent migration of LLC cells toward the
hLEC. Moreover, to further demonstrate the specific
importance of trans-acting secreted lymphatic HS in this
process, addition of purified lymphatic endothelial HS
back into the medium rescued the alteration in tumor
migration resulting from silencing hLEC XylT2 (which
initiates HS chain biosynthesis) in a dose-dependent
manner (Figure 3D). This was carried out for invasion by
both LLC cells and H1650 lung carcinoma cells.
Heparan sulfate secreted by lymphatic endothelium
activates CCL21-dependent tumor cell migration signaling
pathways in trans
We examined whether genetic alteration of lymphatic-
secreted HS might (in-trans) play a key role in mediat-
ing activation of migration signaling in the tumor cells.
Conditioned medium (CM) harvested from HS-targeted
hLEC was applied to cultured LLC cells, and the cells
were examined for the activation of two migration-
related signaling intermediates: focal adhesion kinase
(FAK) and glycogen synthase kinase 3b (GSK3b) (Figure
4A), both of which are activated in migrating tumor
cells through phosphorylation. Compared to LLC expo-
sure to basal growth medium, exposure to CM har-
vested from control (siDS) hLEC led to robust FAK and
GSK3b phosphorylation. Exposure to CM from control
hLEC in the presence of CCL21 blocking antibody, or to
CM collected from siNdst1- or siXylT2-targeted hLEC,
abrogated phosphorylation of the kinases (see also quan-
titative data in Figure 4A). Interestingly, altering lym-
phatic HS in the CM did not appear to alter the
phosphorylation of mitogen activated protein kinase
Erk1/2 in tumor cells in response to CM exposure (Fig-
ure 4B), indicating that targeting HS in the lymphatic
CM may specifically affect migration signaling pathway
activation in CM-exposed tumor cells.
Lymphatic endothelial HS serves as a co-receptor for
chemokine-receptor binding on the surface of tumor
cells, and altering HS sulfation alters chemokine-receptor
association
We examined whether HS produced into CM of hLEC
is required for binding of CCL21 to its receptor on lung
carcinoma cells exposed to the medium. Specifically,
CCL21-CCR7 association on carcinoma cells in the
presence of CM harvested from control versus
Figure 4 Lymphatic-secreted HS activates tumor-cell migration
signaling pathways in trans. A. Serum-free basal endothelial
growth medium or conditioned medium (CM) harvested from hLEC
treated as indicated was applied to cultured LLC for 10 min. The
LLC were lysed and the indicated target proteins were detected by
Western immunoblotting. A representative gel image (top) as well
as normalized densitometric quantification (below) from three
independent experiments is shown. Relative protein expression was
calculated as the densitometric ratio of phosphorylated protein to
that of corresponding total protein, and normalized to the basal
value. *P < 0.05, as compared to LLC treated with CM from control
hLEC (CM-siDS). B. In separate experiments, the effects of blocking
CCL21 (siDS + aCCL21) or treatments that alter HS biosynthesis
(siNdst1 or siXylT2) on CM-mediated Erk1/2 phosphorylation were
examined.
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ried out for both LLC tumor cells (Figure 5A) as well as
human lung carcinoma cells (Figure 5B) using a proxi-
mity ligation assay (PLA) wherein the proximity of anti-
bodies applied to primary ligand (CCL21) and receptor
(CCR7) protein targets was measured through the use of
novel bifunctional secondary antibodies. The assay
generates a fluorescent signal only when the antibody-
labeled ligand and receptor protein targets are in close
proximity [41]. It should be noted that bound CCL21
detected in the assay results from presence of endogen-
ous CCL21 in the CM (i.e., there was no addition of
exogenous CCL21 in the assay). To test the CM from
HS-targeted hLEC in the assay, HS biosynthesis in the
hLEC was targeted through either siNdst1 (targeting HS
sulfation) or siXylT2 (targeting HS chain initiation), and
the hLEC conditioned media were collected. The
engagement of numerous cell-surface CCL21:CCR7
complexes was noted upon exposure of LLCs to CM
from control (scrambled-duplex RNA -treated) hLEC
(Figure 5A; CM-siDS). On the other hand, reduction in
CCL21:CCR7 complexes was noted upon exposure of
LLCs to CM from siNdst1 targeted hLEC, and further
reduction occurred upon exposing the cells to siXylT2-
targeted CM (Figure 5A, graph). The exposure of
human H1650 lung carcinoma cells to the CM from
siNdst1- or siXylT2-targeted hLEC also resulted in abro-
gation of CCL21:CCR7 associa t i o no nt h et u m o rc e l l
surface under similar conditions (Figure 5B).
In separate tests, to examine whether targeting lym-
phatic HS biosynthesis might alter the production of
chemokine by the hLEC, the levels of CCL21 produced
by control (siDS) vs HS-targeted hLEC were examined.
Targeting HS biosynthesis in the hLEC using siNdst1
and siXylT2 did not reduce the expression of CCL21 by
the hLEC (Additional File 1 - Figure S1); and the pro-
tein levels of CCL21 measured in the CM as well as cell
lysates of siNdst1 or siXylT2 targeted hLEC were not
reduced relative to that of control (siDS) (Figure 5C).
These data suggested that reduced receptor-dependent
Figure 5 Heparan sulfate in the lymphatic conditioned medium is required for CCL21 binding to tumor cells. Conditioned medium (CM)
from hLEC transfected with either control (scrambled duplex) RNA (siDS) or siRNA targeting the indicated HS biosynthetic enzymes was
harvested and applied to LLCs (A) or H1650 (B) cytospin samples, respectively. Binding of CCL21 in the CM to CCR7 on LLC was detected by
proximity ligation assay (PLA). Representative merged images showing PLA signal (red) and nuclear DAPI stain (blue) were taken by fluorescence
microscopy (400 ×)(A and B photomicrographs; Scale bar, 50 μm.) PLA signal from each field was quantified and indexed to total nuclear area
within the same field (A and B graphs). At least 5 random fields from each group were included for analysis. Mean data was normalized to
control signal (CM-siDS). *P < 0.05,
#P < 0.01, as compared to CM-siDS group. C. For each hLEC siRNA treatment condition, CCL21 in both the
cell lysate (left) and CM were detected by Western immunoblot analysis. Tubulin was probed as a loading control. D. HS was purified from CM
of siDS- or siNdst1-transfected hLEC and the sulfation status examined by disaccharide analysis using liquid chromatography/mass spectrometry.
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by reduced production or availability of CCL21. Thus,
HS secreted by the hLEC might serve an essential func-
tion in mediating specific presentation of soluble lym-
phatic chemokine in trans to cognate receptor on the
tumor cells, including critical clustering/oligomerization
of chemokines that may be necessary for receptor bind-
ing [26,32]. To confirm whether siRNA targeting of
Ndst1 in the hLEC was sufficient to reduce sulfation of
HS glycan chains produced in the CM, we analyzed the
sulfate composition of HS purified from the conditioned
media of siDS vs siNdst1-targeted hLEC by mass spec-
trometry. HS disaccharides purified from the CM of
siNdst1-targeted hLEC showed marked reductions in
N-, 2-O-, and 6-O-sulfation as compared to that of
control (siDS) hLEC (Figure 5D; see also Additional File
2 - Figure S2 for detailed sulfation analysis by disacchar-
ide species). Accordingly, HS purified from siNdst1-
targeted hLEC was characterized by an increase in the
percentage of unsulfated disaccharides as compared to
that of control hLEC.
Lymphatic endothelial cell-surface HS may establish
chemokine gradients by tethering CCL21 to the lymphatic
endothelial surface
Heparan sulfate produced on the surface of lymphatic
endothelial cells may serve as a source for tethering gra-
dients of lymphatic chemokine(s). To test this hypoth-
esis, we examined the presentation of CCL21 on the
surface of cultured hLEC. We initially carried out
heparin affinity chromatography to assess the degree
to which CCL21 binds to heparin-sepharose columns
(Figure 6A). A moderate-to-high degree of salt (0.8 -
1.0 M NaCl) was required to elute recombinant human
CCL21 from the column. Recombinant human FGF-2,
run as a known strong heparin-binding growth factor,
required 2 - 3 M NaCl for elution. In separate studies,
we also used a plate-based method to characterize the
binding interaction of CCL21 with plate-bound heparin
(Additional File 3 - Figure S3), which showed a Kd (8.3
nM) similar to that previously reported for CCL21 inter-
acting with immobilized heparin [42]. In cell-based stu-
dies, a basal level of endogenous CCL21 present on the
hLEC surface, as detected by immunofluorescence,
could be essentially cleared by treatment with hepari-
nase (which destroys cell-surface HS), or by washing
with heparin (Figure 6B, upper panels). Moreover, exo-
genous CCL21 could be “re-loaded” on the cell surface
following heparin wash, while pre-treatment with hepar-
inase rendered the cell surface incapable of binding exo-
genous CCL21 (Figure 6B, lower panels, “+CCL21”),
suggesting that HS plays a key role in maintaining
CCL21 (including endogenous levels) on the hLEC sur-
face. In separate studies, we also found that hLEC
express CCR7 (Additional File 4 - Figure S4). To specifi-
cally examine whether hLEC cell-surface HS might be
required for CCL21-CCR7 association on hLEC, we per-
formed PLA using CCL21 and CCR7 antibodies, and
found that binding of endogenous CCL21 produced by
the hLEC to CCR7 on the hLEC cell surface was sensitive
to altering HS biosynthesis in the hLEC through either
siNdst1 or siXylT2 targeting (Figure 6C). It is noteworthy
that addition of exogenous recombinant CCL21 to con-
trol (siDS) hLEC resulted in a higher level of receptor-
bound CCL21 than that of basal/endogenous CCL21;
however, the difference fell short of statistical significance
(P = 0.09), possibly because of a large number of CCR7
receptor sites already occupied by endogenous CCL21.
Nevertheless, ablation of HS chain biosynthesis (i.e. tar-
geting using siXylT2) also prevented the binding of exo-
genous CCL21 to the cells (data not shown).
Genetic knock-down of lymphatic endothelial HS sulfation
through a lymphatic-specific mutation in Ndst1 impairs
the spread of Lewis lung carcinoma to regional lymph
nodes
Following in vitro results as well as the finding that a
pan-endothelial mutation in Ndst1 was associated with
reduced tumor colonization of regional lymph nodes in
the LLC tumor model (Figure 2), we sought to confirm
w h e t h e rt h a tr e s u l tm i g h th a v es t e m m e df r o ms p e c i f i -
cally altering HS in the lymphatic endothelium. Lym-
phatic vasculature may carry tumor cells directly
between primary tumor and the regional lymph node;
however, in a pan-endothelial HS mutation model (i.e.,
tissue targeting using TekCre, as in Figure 2), the addi-
tional presence of the mutation in blood-vascular
endothelium has the potential to alter HS biosynthesis
in lymph node high endothelial venules (i.e., potential to
also affect blood-borne lymph node metastasis). To
a d d r e s st h i sa n dm a x i m i z eg e netic specificity in vivo,
tumors were established by injecting LLC tumor cells
into the left caudal/medial inguinal fold of Ndst1
f/fProx1
+/CreERT2 mutant mice (N = 10) and Ndst1
f/fProx1
-/
CreERT2 wildtype littermates (N = 10), wherein the Ndst1
mutation could be inducibly driven under control of the
Prox1 promoter, which is expressed exclusively in lym-
phatic endothelium [43]. In preliminary reporter studies,
induction of Cre recombinase in the lymphatic endothe-
lium of Prox1
+/CreERT2 mutants following a schedule of
tamoxifen (administered to both Cre positive and Cre
negative control animals) was confirmed in lymphatic
vessels, including those within lymph nodes, using a Cre
reporter line (Rosa26R)b r e do n t ot h eProx1
+/CreERT2 vs
Prox
-/CreERT2 backgrounds, and staining of tissues with
X-gal (Figure 7A).
Following tumor induction in the compound (Ndst1
f/f
Prox1
+/CreERT2) mutants and their wildtype Cre
- littermates,
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Page 8 of 20Figure 6 Lymphatic endothelial heparan sulfate is required for receptor-dependent display of CCL21 on the lymphatic surface. A.
Binding of human CCL21 (hCCL21) to heparin was examined using heparin affinity chromatography followed by silver staining of salt-eluted
fractions on SDS-PAGE (upper panel). “Pre,” recombinant human CCL21 sample directly loaded onto the silver-stained gel; “FT,” flow-through
from the column. Basic fibroblast growth factor (FGF-2) was run as a positive control (lower panel). B. hLEC were treated as indicated and the
binding of CCL21 to hLEC was examined by immunofluorescence (IF) using anti-CCL21 antibody. hLEC, untreated cells; H’ase, Heparin: hLEC pre-
treated with heparinase or heparin, respectively; H’ase+CCL21, Heparin+CCL21: hLEC pre-treated with heparinase or heparin, respectively,
followed by addition of exogenous human recombinant CCL21 (+CCL21). Representative merged images showing CCL21 signal (green) and
DAPI nuclear stain (blue) were taken under 100× magnification. (Scale bar, 100 μm.) C. hLEC were transfected with either control RNA (siDS) or
siRNA targeting HS biosynthetic enzymes Ndst1 or XylT2. Binding CCL21 to CCR7 on hLEC was detected by proximity ligation assay (PLA).
Representative merged images showing PLA signal (red) and nuclear DAPI stain (blue), imaged using fluorescence microscopy (400×; Scale bar,
50 μm). PLA signal from each field was quantified and indexed to total nuclear area within the same field, and mean values for each condition
were graphed (bottom). At least 5 random fields from each group were included for analysis. Mean data was normalized to control signal (siDS).
*P < 0.01, as compared to control.
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Page 9 of 20Figure 7 Genetic alteration of lymphatic endothelial heparan sulfate biosynthesis impairs tumor metastasis to regional lymph nodes.
A. Cre reporter testing in the inducible Prox1
+/CreERT2 model: Bilateral subiliac lymph nodes (LN) were isolated from Prox1
+/CreERT2Rosa26R reporter
mice (”Prox1+/CreERT2“, lower panel) or their Prox1
-/CreERT2Rosa26R littermates (”Prox1-/CreERT2”, upper panel) after intraperitoneal injection of
Tamoxifen for 5 consecutive days; and stained with X-Gal (showing as deep blue stain in Cre positive lymph nodes). Right panels: subiliac LNs
from A were sectioned and stained for LYVE-1 (brown) and X-Gal (blue); and imaged under 400 × magnification (Scale bar, 50 μm). For tumor
establishment, LLC tumor cells were injected subcutaneously into the left caudal-medial inguinal region of Ndst1
f/fProx1
+/CreERT2 mice (N = 10)
and their Ndst1
f/fProx1
-/CreERT2 wildtype littermates (N = 10) following a 5-day tamoxifen dosing schedule. Following 14 days of primary tumor
growth, the left subiliac regional LN from each mouse was isolated. B. Comparison of primary tumor volumes from Cre postive vs Cre negative
mice at time of experiment termination and lymph node harvesting. C. Representative photomicrographs of pan-keratin stained LN histologic
sections are shown above plotted data on the left, which shows quantified pan-keratin signal per LN for each mouse. Graph to the right shows
plotted data for degree of CCL21 immunoreactive signal per LN (and representative photomicrographs of CCL21 staining from Cre positive vs
Cre negative animals above the graph). LN staining signal from both groups was imaged under 100× magnification, quantified as pixel values
per LN using NIH Image J software, and normalized to the average pixel value/LN in Ndst1
f/fProx1
-/CreERT2 control group. *P < 0.05,
#P < 0.01, for
comparison of mean mutant vs control group values. D. LNs from both groups were co-stained with CCL21 (blue) and LYVE1 (brown) (left two
panels) or pan-keratin alone as a marker for metastatic tumor cells (blue signal, right panel). Scale bars, 100 μm for 100× and 50 μm for 400×
magnification.
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Page 10 of 20when the primary LLC tumor size reached ~0.5 cm in dia-
meter (confirmed to be equivalent in both Cre positive
mutants and Cre negative wildtype littermates; Figure 7B),
we isolated regional subiliac lymph nodes, and analyzed
nodal tumor metastases through IHC analysis of lymph
node sections for pan-keratin. Mutant lymph nodes were
characterized by a striking reduction in tumor deposits, as
compared to that in Cre negative control littermates
(Figure 7C, left graph), indicating that appropriately sul-
fated lymphatic endothelial HS is critically required for
lymph node metastasis. It should be noted that this LLC
tumor model was characterized by absence of intratumoral
lymphangiogenesis in the primary tumors of wildtype mice;
however, scant LYVE-1 positive lymphatic vessels were
found surrounding the tumors at the time of lymph node
harvest. Regional lymph nodes were characterized by lym-
phatic proliferation in tumor-bearing mice (with a mean
2.85 - fold increase in the total lymph node lymphatic
conduit, as measured by LYVE-1 immunoreactivity, in
tumor-associated lymph nodes as compared to non-tumor
associated nodes; P = 0.004). Among tumor-bearing mice,
lymphatic vessel density in the lymph nodes from Ndst1
mutants was lower than that of their wildtype littermates
(Additional File 5 - Figure S5), although the difference fell
short of meeting statistical significance. With respect to
metastases in regional lymph nodes draining the tumors,
however, there were striking differences in mutant versus
wiltype lymph nodes. The regional lymph nodes from
Ndst1
f/fProx
-/CreERT2 wildtype littermates showed large
areas of CCL21 positive cells that were found to tightly
localize to areas of pan-keratin positive tumor metastases
(Figure 7C, compare pan-keratin and CCL21 photomicro-
graphs from a representative Cre negative animal, shown
above graphs). Some CCL21 staining showed spotty co-
localization with LYVE-1 along the walls of lymphatic ves-
sels in the lymph nodes (Additional File 6 - Figure S6),
although most immunolocalization of the chemokine
ligand was associated with metastatic tumor cells. On the
other hand, in lymph nodes of Ndst1
f/fProx1
+/CreERT2
mutants, regional lymph nodes were characterized by
not only minimal pan-keratin positive tumor deposits
(Figure 7C, left graph); but in contrast to wildtype litter-
mates, the chemokine showed markedly reduced presence/
localization of CCL21 with pan-keratin positive tumor
areas (Figure 7C, compare representative photomicro-
graphs from Cre positive animal above graphs; and Figure
7D, showing another example at 100× and 400×). This sug-
gested that the specific loss of Ndst1 in the lymphatic
endothelium reduced not only lymph node metastasis, but
also the ability of CCL21 to associate with tumor cells in
the lymph node sections.
Discussion
In this study, we demonstrate that altering HS biosynth-
esis in the lymphatic endothelium in vivo results in
altered regional lymph node colonization by tumor cells
in experimental mouse carcinomas. In cell-based studies,
targeted disruption of lymphatic endothelial HS bio-
synthesis altered the ability of the lymphatic endothe-
lium to attract tumor cells in a chemokine-dependent
manner. The findings demonstrate the genetic impor-
tance of a lymphatic endothelial glycan (i.e., heparan
sulfate) on cell traffic in the lymphatic microenviron-
ment. Specifically, our findings focused on the lymphatic
trafficking of carcinoma cells during lymph node metas-
tasis. Exploring possible mechanisms in cell-based sys-
tems revealed unique and critical roles served by
lymphatic endothelial HS in mediating lymphatic-direc-
ted tumor cell migration in response to the chemokine
CCL21. This occurred through distinct roles served by
two forms of lymphatic endothelial HS: (1) Lymphatic-
secreted HS (presented on proteoglycans in lymphatic
endothelial conditioned medium), which appeared to
serve as a soluble co-receptor for CCL21-CCR7 associa-
tion and migration signaling on tumor cells; and (2)
Lymphatic cell-surface HS (displayed on lymphatic
membrane-bound proteoglycans), which appears to con-
centrate CCL21 on the lymph endothelium, and thereby
serves as a means by which lymphatic vascular chemo-
kine gradients may be regulated in vivo.
Unique role for heparan sulfate in the lymphatic
microenvironment: Novel control of tumor migration by
an important chemokine
As a result of unique sulfate modifications, HS has been
identified as a mediator of chemokine binding in both
cell-free preparations [26] and a limited number of cell
biological contexts. In particular, HS has been found to
play roles in chemokine-dependent inflammatory leuko-
cyte extravasation [37] as well as the binding of inflam-
matory chemokines to ECM in clinical rheumatoid
arthritis specimens [28]. To date, however, there are no
data examining the genetic importance of HS in the
lymphatic microenvironment and lymph node tumor-
cell trafficking; and in carcinoma, the possible genetic
importance of HS as a mediator of chemokine signaling
and/or gradients has not been reported. While some
recent data pointed to the importance of the CCL21-
CCR7 axis during tumor-lymphatic chemo-attraction
[8,9], we also noted that CCL21 is endowed with a
C-terminus that is particularly rich in basic amino acids
that may contribute to heparin binding [44], which we
confirmed by heparin affinity chromatography using
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Page 11 of 20recombinant CCL21 (Figure 5A). With these considera-
tions in mind, we found that pre-treatment of LEC with
heparinase (to destroy cell-surface HS) inhibited murine
Lewis lung carcinoma (LLC) invasion into the LEC-
embedded collagen (Figure 1B), a process that was also
CCL21 dependent. Blocking biosynthesis of HS by the
LEC through siRNA resulted in similar effects in both
murine and human lung carcinoma cells.
These insights led us to examine regional (inguinal)
lymph node colonization by LLC tumor cells following
experimental tumor establishment in syngeneic mice
bearing a pan-endothelial alteration in HS biosynthesis.
Initially, mutant (Ndst1
f/fTekCre
+) mice showed not only
a reduction in LLC metastasis to regional lymph nodes,
but also a reduction in CCL21 associated with meta-
static tumor colonies (Figure 2B). Nodal metastasis in
subcutaneous Lewis lung carcinoma models has been
shown to occur via the afferent lymphatic conduit that
intervenes between primary tumor and regional lymph
nodes [45]. The findings support an important role for
HS in mediating chemokine-dependent lymphatic-borne
trafficking of tumor cells to the regional lymph nodes.
However, this model may be somewhat limited by the
fact that Tek drives pan-endothelial Cre activation; and
we could not fully rule out the possibility that differ-
ences in regional lymph node colonization might be
based on not only lymphatic Ndst1 deficiency, but also
blood-endothelial Ndst1 deficiency. Nevertheless, the
model was characterized by relatively heavy tumor
metastasis to the regional lymph node, while very few/
rare pan-keratin positive foci could be detected in the
contralateral inguinal lymph node (or the more distant
cervical lymph node; data not shown). This is consistent
with the likelihood that lymph node metastases to regio-
nal lymph nodes occurred via intervening lymphatic vas-
culature. Moreover, the model was characterized by an
absence of intra-tumor lymphatic vessels, and compar-
able lymphatic vessel densities in the peri-tumor tissue
of mutant vs wildtype littermates. Thus, targeting HS
sulfation in the lymph endothelium resulted in altered
nodal metastasis in the mutant mice while the anatomic
extent of the peri-tumoral lymphatic beds in mutant
and wildtype littermates were comparable.
Mechanistic considerations: Secreted and cell-surface
bound heparan sulfate
How might one explain the marked alteration in nodal
metastasis that was observed in the setting of the gly-
can-altered lymphatic endothelial conduit? Lymph node
- colonizing tumor deposits in wildtype littermates were
associated with abundant CCL21 that localized with the
tumor deposits. However, CCL21 immunoreactivity
associated with the limited tumor deposits found in
mutant lymph nodes was reduced (Figure 2B, lower
panels). Two possible mechanistic explanations that we
explored involved alterations in chemokine-dependent
tumor cell behavior that might result from mutation of
either (1) HS secreted by the lymph endothelium, or (2)
HS displayed on the lymphatic endothelial cell surface.
W ef i r s th y p o t h e s i z e dt h a tg e n e t i ca l t e r a t i o no fH S
secreted by the lymphatic endothelium might disrupt
the presentation of soluble CCL21 to CCR7 receptor
(with altered downstream migration signaling) on the
surface of metastasizing tumor cells, a phenomenon
reminiscent of the ability of sulfated domains on HS to
critically “cluster” heparin-binding chemokines (e.g., as
in oligomerization of IL-8 or CCL2) for receptor presen-
tation [32]. We also hypothesized that disrupting the
sulfation of HS expressed on the lymphatic cell surface
might alter gradient distributions of CCL21 tethered
and concentrated on the HS chains. As in the case of
vascular endothelial HS mediating MIP-2 gradients
needed to drive trans-endothelial neutrophil migration
[46], lymph endothelial HS might similarly mediate
CCL21 gradients within lymph node lymphatic capil-
laries that in turn may facilitate the trafficking of tumor
cells to the lymph node.
Mechanistic evidence for the first hypothesis (i.e., lym-
phatic-secreted HS serving as a chemokine co-receptor)
was supported by initial cell-based studies wherein lym-
phatic endothelia were separated from tumor cells by
lymphatic conditioned media (Figure 3A). Heparan sul-
fate is known to interact with basic amino acid motifs
on several chemokines, and may serve as a co-receptor
for the activation of certain chemokine receptors by spe-
cific chemokines. A known example is the requirement
for HS during the activation of CXCR4 by CXCL12/
SDF-1a [47]. However, evidence for the genetic impor-
tance of the glycan in mediating receptor binding and
activation by such chemokines in biological systems is
lacking. Given the chemokine- and lymphatic HS-depen-
dent behavior of tumor cells demonstrated in the migra-
tion assays (Figure 3B, C), we focused on the CCL21/
CCR7 axis, and asked whether genetic alteration of lym-
phatic-secreted HS might (in-trans)p l a yak e yr o l ei n
mediating activation of migration signaling in the tumor
cells. The results identified key roles for lymphatic HS
secreted by the LEC into the conditioned medium on
tumor-cell migration behavior. In addition, the presence
of HS in the conditioned medium supported phosphory-
lation of both FAK as well as the migration-associated
signaling intermediate GSK3b, a condition that was
abolished by blockade of CCL21 in the conditioned
medium or by inhibiting the biosynthesis of HS secreted
into the conditioned medium (Figure 4). The latter was
accomplished by siRNA-mediated targeting of HS chain
initiation on lymphatic proteoglycans secreted into the
medium (siXylT2) or by targeting HS chain sulfation
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Phosphorylation of the mitogen Erk1/2 in tumor cells in
response to CM exposure, however, was not sensitive to
siRNA mediated targeting of HS in the CM (Figure 4B),
implying that the activation of chemokine-mediated
migration-associated pathways (i.e., p-FAK, p- GSK3b)
in the tumor cells appears to be more sensitive to the
HS alteration than the effect on activation of a major
mitogen (i.e., p-Erk1/2) pathway. Importantly, we ques-
tioned whether these signaling alterations on tumor
cells that depend on the state of HS in the conditioned
medium were associated with “upstream” alterations in
the ability of CCL21 to associate with CCR7 G-protein
coupled receptors on tumor cells. This appeared to be
the case, as demonstrated through the use of proximity
ligation assays using cultured tumor cells exposed to the
intact versus HS-targeted conditioned media (Figure 5A,
B). The findings were not trivially explained by a simple
reduction in lymphatic chemokine production (i.e., in
the conditioned medium) as a result of HS targeting in
the LEC (Figure 5C). Rather, it appears that disrupting
the biosynthesis of HS (which was also confirmed at the
level of glycan sulfation for Ndst1 targeting; Figure 5D)
may disrupt the presentation of HS-associated CCL21
chemokine to its receptor. This is reminiscent of solu-
tion-phase studies demonstrating critical oligomerization
of some chemokines by glycosaminoglycans [26], and
the findings thus demonstrate the genetic importance of
the glycan as it serves (in trans) to effect chemokine-
dependent tumor cell behavior in vitro and lymph node
colonization in vivo.
Another mechanistic possibility is that disruption of
HS expressed on the lymphatic endothelial surface may
alter gradients of CCL21 concentrated on HS chains on
the lymphatic endothelial surface and peri-lymphatic
ECM of the lymph node. In the lymph node, in addition
to expression in the high endothelial venules, CCL21 is
expressed within the lymphatic endothelial-rich T-cell
zones and inner lymph node cortex [14]. It is also
expressed by the lymphatic endothelium of multiple
other tissues. Heparan sulfate expressed on lymphatic
membrane-bound as well as peri-lymphatic matrix pro-
teoglycans might critically serve as a scaffold for tether-
ing CCL21 gradients produced by lymphatic vessels. It
should also be recognized that CCL21 may bind to
other lymphatic endothelial proteins, such as podoplanin
[48], which might also contribute to gradient formation
and/or temper alterations in CCL21 gradients disrupted
by targeting HS in vivo. Nevertheless, altering the bio-
synthesis of lymphatic HS may thus disrupt the ability
of CCR7-expressing tumor cells to migrate/extravasate
from the lymphatic vascular lumen of afferent lymphatic
vessels (entering the lymph node) toward the chemo-
kine-rich lymphatic vessel wall and surrounding matrix.
While the latter anatomic region is not characterized by
a basement membrane per se, it is a region wherein per-
lecan, a major secreted HS proteoglycan, has been iden-
tified [27]; and we also identified perlecan as the major
secreted HS proteoglycan expressed by cultured primary
lymphatic endothelial cells (Additional File 7 - Figure
S7). Accordingly, any lumen-to-matrix flow of lymph
entering the lymph node via afferent lymphatic vessels
may support such a gradient, and trafficking CCR7-posi-
tive cells may extravasate and colonize the lymph node
along the same pathway. In addition to HS on peri-lym-
phatic matrix proteoglycans, the findings in Figure 6
support the importance of lymphatic cell-surface bound
HS proteoglycans in serving as an important source for
CCL21 gradients. The absence of such gradients in the
setting of HS disruption may thus limit the ability of the
CCR7-expressing tumor cells to traffic out of afferent
lymphatic vessels in the lymph node and colonize the
lymph node parenchyma. Finally, it is also possible that
integrins play a critical role (reviewed in [49]), working
together with HS proteoglycans during cell adhesion
and lymphatic transmigration events that contribute to
this process.
Re-visiting heparan sulfate in vivo: Lymph node
metastasis in the setting of a lymphatic-specific heparan
sulfate alteration
Our findings thus suggested at least two mechanisms
whereby lymphatic HS might be specifically required for
CCL21-mediated colonization of lymph nodes by tumor
cells: Namely, through the ability of lymphatic endothe-
lial HS to as serve as either a co-receptor for chemo-
kine-mediated tumor migration signaling or as an
essential scaffold for peri-lymphatic chemokine gradients
(or both). With these mechanisms in mind, the in vivo
effects of a pan-endothelial deficiency in HS sulfation on
regional lymph node metastasis (Figure 2) suggested that
a lymphatic-exclusive mutation in Ndst1 might also dis-
rupt regional lymph node metastasis using the same
tumor model. This was achieved through the use of a
mouse construct wherein Cre was driven by the lympha-
tic-endothelial specific promoter Prox1 [50]; with the
added advantage that conditional mutants could be
induced to develop the lymphatic-specific alteration in
Ndst1 (through administration of tamoxifen to activate
Prox1 driven Cre) exclusively in lymphatic vessels imme-
diately prior to the experiment. Mice therefore did not
develop with a tissue-targeted Ndst1 deficiency (as they
would have in the TekCre model), and we applied a
tamoxifen induction schedule that resulted in efficient
Cre activation in lymphatic vessels, including those in
lymph nodes (Figure 7A). Using this model, a marked
reduction in lymph node metastasis was noted in
Ndst1
f/fProx1
+/CreERT2 mutants (Figure 7C). Importantly,
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nodes of Ndst1
f/fProx1
+/CreERT2 mutants, while the signal
localized to regions of tumor deposits, the relative
expression of CCL21 in those regions was markedly
reduced (Figure 7D, bottom panels) as compared to that
in the lymph nodes of Cre negative control littermates
(Figure 7D, upper panels), where tumor deposits were
essentially fully decorated with CCL21. These findings
parallel our in vitro results that examine lymphatic-HS
dependent tumor-cell binding and responses to CCL21
(Figures 3, 4, 5), and support an important role for HS
produced by the lymphatic endothelium in mediating
the binding of CCL21 to node-metastatic tumor cells in
vivo.
In addition to considering limitations in the applicabil-
ity of our findings, it is also worthwhile to re-examine
o u rc u r r e n tk n o w l e d g ea b o u tt h en a t u r eo fv a s c u l a r
endothelial disorders involving altered Ndst1 expression.
First of all, while the above proof-of-principle studies
were carried out using both mouse as well as human
lung carcinoma cell lines, we cannot over-generalize our
findings and mechanisitic insights to lymph node metas-
tasis from all primary lung carcinomas. Variation might
occur in relation to CCL21 distribution/expression, the
degree of CCR7 over-expression by specific tumors, or
even the degree of HS expression in distinct lymphatic
vascular beds. Although this is the first study that speci-
fically targets HS expression in the lymphatic endothe-
lium, we have gained some insights from other work
that has focused on vascular disorders associated with
alterations in vascular Ndst1 expression. It is note-
worthy, for example, that experimental blood-endothe-
lial as well as vascular smooth muscle - targeted
alterations in Ndst1 expression may result in marked
alterations in chemokine-mediated inflammatory cell
infiltration in the setting of transplant [51] as well as
altered growth factor dependent vascular proliferation
responses [52]. Further work is necessary to characterize
alterations in lymphatic endothelial Ndst1 expression in
human lymphatic disease. It is possible, from the find-
ings herein, that variations in expression might result in
altered carcinoma cell trafficking patterns.
Conclusions
These findings support important roles for lymphatic HS
in mediating both the ability of tumor cells to colonize
lymph nodes and the ability of chemokine to bind and
effect the migration of tumor cells in a receptor-dependent
manner. Figure 8 summarizes the mechanisms whereby
heparan sulfate produced by the lymphatic endothelium
may critically mediate chemokine-dependent lymph node
trafficking by tumor cells. The mechanisms, involving co-
receptor as well as gradient-scaffolding functions by the
glycan, may apply to both invasion of lymphatic vessels in
the primary tumor (Figure 8A) as well as lymphatic extra-
vasation and colonization by lymph-borne tumor cells
entering regional lymph nodes (Figure 8B). It is important
to recognize that while we have demonstrated how this
applies to tumor cell invasion (including migration signal-
ing) by a prototypical heparin-binding chemokine
(CCL21), the mechanisms may also apply collectively to
other HS-binding chemokines (e.g., CXCL12, among
others) that may function in redundant manners to drive
lymphatic tumor cell traffic. Further studies are needed to
weigh the relative impact of HS-mediated chemokine gra-
dients and/or co-receptor functions on migrating tumor
cells in distinct tumor models in vivo. Nevertheless, the
genetic proof-of-principle herein suggests that targeting
HS in the lymphatic system may have significant effects in
altering tumor-lymphatic cell traffic as well as lymph node
metastasis in clinical cancer.
Methods
Cell culture and treatments
Primary human lung lymphatic endothelial (hLEC) cells
(Lonza) were cultured in fully supplemented EBM2
endothelial basal medium (with EGM2 bullet kit; Lonza).
Cells were determined to be >99% pure at the 3
rd passage
by nuclear staining for Prox-1 via immunofluorescence.
Lewis lung carcinoma (LLC) cells (ATCC) and stable
GFP-expressing LLC cells were cultured in DMEM (Invi-
trogen) supplemented with 10% FBS (Atlanta Biologicals).
Human adenocarcinoma cells H1650 (ATCC) were cul-
tured in RPMI-1640 (Invitrogen) supplemented with 10%
FBS. All siRNA duplexes were from IDT (Coralville, IA),
and transfected into cells according to manufacturer
instructions. For heparinase treatment, cells were incu-
bated with heparinases I, II and III (kindly provided by
Dr. J.D. Esko) in serum-free EBM2 medium at 37°C, 5%
CO2 for 4 h. For heparin wash, the cells were washed
with PBS, incubated in 100 μg/mL heparin (Sigma) in
PBS at room temperature for 10 min with gentle shaking
and washed with PBS twice to remove any residual
heparin. To block specific chemokine or chemokine
receptor signaling, cells were incubated with a-CCL21
(1:100), a-CCL5 (1:100) or a-CCR7 (1:100, R&D) at
37°C, 5% CO2 for 30 min (for harvesting CM) to over-
night (for transwell migration assay).
Modified transwell migration assays
To assess the mobility of tumor cells toward hLEC, a
modified transwell migration assay was performed in
two ways that differed in the manner hLEC were plated.
For collagen matrix-based invasion studies, 1 × 10
5
hLEC were embedded into 100 μL of type I collagen gel
containing 2.7 mg/mL PureCol (Advanced Biomatrix,
San Diego, CA) in 1X DMEM (pH 7.3), applied as a
liquid to cover the lower side of transwell inserts
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5% CO2 for six hours. Inserts were then inverted and
placed into 24-well plates (500 μL/well) containing pre-
warmed basal (i.e., growth factor free, un-supplemented)
EBM2 with 2% FBS. For migration toward conditioned
medium (CM) overlying monolayer-cultured hLEC, 5 ×
10
4/well hLEC were seeded directly into 24-well plate,
and treated accordingly. For both assays, 1 × 10
5 H1650
cells pre-labeled with Calcein AM (following the manu-
facturer instructions; Invitrogen) or stable GFP-expres-
sing LLC cells were resuspended in 100 μLo fE B M 2
with 2% FBS and loaded on top of the insert. The
migration proceeded in a 37°C, 5% CO2 incubator for
overnight. Inserts were then treated with either 0.2%
type I collagenase (Sigma) at 37°C for 1 h (for collagen
matrix-based migration assay) or trypsin-EDTA (Invitro-
gen) for 5 min (for chemotaxis migration assay) with
gentle rocking. Digests (including media from lower
wells) were collected, transferred to eppendorf tubes,
and centrifuged at 5,000 × g for 5 min. Cell pellets were
resuspended in 15 μLP B S ,w i t h1 . 5μL samples loaded
onto a 96-well Terasaki plate (Robbins Scientific), and
imaged under a fluorescence microscope (Nikon Eclipse
80i). Images were taken under 40× magnification and
analyzed with NIH Image J software. All assays were set
up in triplicate with at least three independent experi-
ments performed for each assay. In a subset of chemo-
taxis migration assays, purified HS isolated from the
CM of control hLEC was dosed into the lower wells of
siXylT2 targeted hLEC. To assess dose-response, frac-
tions of the total HS needed to achieve full rescue of
invasion (i.e., to a degree comparable to that achieved
toward siDS control hLEC) by the tumor cells were
added/tested in separate wells containing siXylT2 tar-
geted hLEC in the lower wells. Isolation/purification of
HS from the LEC was carried out according to the
method of Bame, et al. [53].
Reverse-transcription followed by quantitative real-time
PCR (RT-qPCR)
Total RNA was extracted from cells using RNAqueous
4-PCR kit (Ambion) and reverse transcribed into cDNA
with SuperScript III kit (Invitrogen) according to the
manufacturers’ instructions. Real-time PCR was per-
formed with iQ Sybr Green Supermix Kit (BioRad). The
primer sequences (5’ to 3’) used for real-time PCR were
as follows: human Ndst1 forward, GGACATCTGGTC-
TAAG, and reverse, GATGCCTTTGTGATAG; human
Figure 8 Summary of mechanistic considerations: Role of lymphatic endothelial heparan sulfate in chemokine-mediated lymph node
metastasis. A. In peripheral lymphatic vessels (e.g., lymphatic vascular bed of a primary tumor), HS-binding chemokines produced by the
lymphatic endothelium such as CCL21 may “cluster” on lymphatic-bound as well as secreted HS proteoglycans. In the setting of intra-lymphatic
flow (thin arrows), spatial gradients of the chemokine scaffolded on HS chains in the extracellular matrix and lymphatic endothelium may
facilitate tumor-cell migration into lymphatic vessels. This may occur in coordination with other adhesion systems such as integrins or selectins.
Clustering of chemokines (as dimers in this example) on HS in the peri-lymphatic extracellular matrix may also be critical for receptor activation
(e.g., CCR7) on migrating tumor cells. Targeting HS biosynthesis may thus alter chemokine-receptor interactions (large black arrow, mechanism
“1”) as well as chemokine gradients (large grey arrow, mechanism “2”). B. In the lymph node, similar principles may apply; however, the direction
of trans-lymphatic flow and chemokine gradient are reversed, facilitating extra-vasation (colonization) of trafficking tumor cells expressing
cognate chemokine receptors. Interfering with the biosynthesis of lymphatic heparan sulfate (e.g., genetically targeting the sulfation of HS
through lymphatic endothelial Ndst1 mutation) may thus abrogate lymph node metastasis by altering such co-receptor and gradient-mediating
functions served by the glycan.
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reverse, ATTGCTCAGTTCCCCATCTG; human CCL
21 forward, GCCTTGCCACACTCTTTCTC, and
reverse, CAAGGAAGAGGTGGGGTGTA; human CCR7
forward, TTCTTCACTGTCCTCCAAGC, and reverse,
ACATTTCCCTTGTCCTCTCC. The PCR condition was
95°C for 3 min followed by 40 cycles of 95°C for 30 sec,
59°C for 30 sec and 72°C for 30 sec. Relative expression
of target gene against b-actin was calculated using 2
-ΔΔCt
method [54]. Primers used for quantitative PCR of major
HS proteoglycan core proteins produced by hLEC (Addi-
tional File 7 - Figure S7) are described in Additional File
8 - Table S1.
Preparation of conditioned medium (CM) from hLEC
To harvest conditioned medium (CM) for Proximity
Ligation Assays (PLA; Duolink) and for HS isolation,
hLEC were treated accordingly, washed with PBS, and
incubated in basal EBM2 containing 5% diethylami-
noethyl (DEAE) anion-exchange treated FBS (glycosami-
noglycan-free) for 24 h. To harvest CM for stimulating
LLC cells in all other assays, hLEC were incubated in
basal EBM2 medium alone for 5 h. The supernatant was
then collected and briefly centrifuged to remove the cell
debris.
Purification of HS from hLEC conditioned medium and
characterization HS disaccharides
H Sw a si s o l a t e df r o mt h eC Mo fh L E Cc e l l sa sp r e -
viously described [53], and digested into disaccharides
via enzymatic depolymerization with heparinase (2 IU
each of heparin lyases I,II,III; IBEX) overnight at 37°C in
50 μl buffer (40 mM ammonium acetate and 3.3 mM
calcium acetate, pH 7). (For some cell-based studies,
purified HS was used intact (i.e., undigested), and dosed
into the cell medium.) HS disaccharide analysis was car-
ried out using quantitative liquid chromatography/mass
spectrometry according to published methods [55].
Briefly, HS digests were dried down, and to each sample
the following were added: [
12C6]aniline (15 μl, 165
μmol) and 15 μlo f1MN a C N B H 3 (Sigma/Aldrich)
freshly prepared in dimethylsulfoxide: acetic acid (7:3,
vol/vol). Aniline labeling of the reducing ends of disac-
charides was carried out at 37°C for 16 hr and products
were dried down. The derivatized disaccharides were
separated on a C18 reversed phase column (0.46 ×
25 cm; Vydac) with ion pairing agent (dibutylamine,
Sigma/Aldrich) [56]. Eluted ions of interest were moni-
tored in negative ion mode (on a classic quadrupole ion
trap mass spectrometer; Thermo-Finnigan). The capil-
lary temperature and spray voltage were maintained at
140°C and 4.75 kV, respectively. Accumulative extracted
ion current was computed, and data were analyzed
(Qual Browser software; Thermo).
Western immunoblots
Cells were lysed in RIPA buffer (Teknova) supplemented
with protease inhibitor cocktails (Sigma) and phospha-
tase inhibitor cocktails (Santa Cruz). The protein con-
centration was determined with Protein assay dye
reagent (BioRad). A total 50 to 70 μg protein was sepa-
rated on a 4%-20% gradient gel (BioRad), electrotrans-
ferred to a nitrocellulose membrane, probed with one of
the following primary antibodies: CCL21 (1:1000, R&D),
FAK (1:100), p-FAK (Tyr397, 1:1000) (Santa Cruz, CA),
p-GSK3b (Ser9, 1:1000) (Enzo Life Sciences), GSK3b
(1:1000, Upstate), Tubulin (1:10,000, Sigma) and Ndst1
(1:1000, Abcam). Additional primary antibodies included
anti-CCR7 (1:5000, Novus) and anti-b-actin (1:5000,
Sigma). After two washes with Tris-buffered saline/0.1%
Tween-20 (TBST), the membrane was incubated with
an HRP-conjugated secondary antibody and visualized
using SuperSignal chemiluminescent substrate (Pierce).
The signal density was quantified using Adobe Photo-
shop 7.0.
Detection of CCL21 in conditioned medium (CM) from
hLEC
To measure the secreted CCL21 by hLEC, 3 × 10
5 hLEC
cells were seeded onto wells of a 6-well plate, and trea-
ted accordingly (i.e., siRNA/transfection treatments tar-
geting HS biosynthesis and appropriate control
transfections). Cells were washed with PBS once and
basal EBM2+5% FBS was added to the cells. A transwell
insert (0.4 μm in pore size, Corning, Cat. #3412) was
placed into each well and 100 μL Heparin sepharose
(GE Healthcare, Piscataway, NJ) pre-washed with PBS
and resuspended in 1 mL EBM2/5% FBS was loaded on
top of the insert. The cells were incubated in 37°C, 5%
CO2 incubator for 24 h. Following the incubation, the
transwell insert was transferred to a clean 6-well plate
and Heparin sepharose was collected with PBS wash
until no sepharose beads were visible on the insert. All
washes were pooled and briefly centrifuged with super-
natant carefully removed. 2X protein loading buffer and
b-mercaptoethanol were added to the sepharose beads
to a final concentration of 1 × and 5% respectively. The
samples were boiled at 95°C for 5 min, loaded onto a
SDS-PAGE gel, and CCL21 was detected by Western
immunoblot.
Immunofluorescence
hLEC growing on glass coverslips were treated accord-
ingly, fixed in 4% paraformaldehyde, blocked with PBS/
1%BSA at room temperature for 1 h and stained with
anti-CCL21, anti-CCR7 (R&D, 1:100) or isotype-
matched control IgG (1:100, Vector Lab) at 4°C
overnight. After PBS wash several times, the cells were
incubated with Biotinylated secondary antibody (1:500,
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Alexa 488-conjugated streptavidin (2 μg/mL, Invitrogen)
and mounted with VectaShield with DAPI (Vector
Labs). All images were taken under a fluorescence
microscope (Nikon Eclipse 80i; 100× or 400×).
Heparin affinity chromatography
Heparin affinity chromatography was used to assess the
binding of CCL21 and bFGF to column-immobilized
heparin. Briefly, 100 μL Heparin sepharose was loaded
onto chromatography column (BioRad) and equilibrated
in wash buffer (0.15 M NaCl in 25 mM HEPES, pH
7.2). Human CCL21 or bFGF (2 μg, Peprotech) was
then added to the column in 100 μL wash buffer. Step-
wise elutions (200 μL each) with wash buffer containing
increasing [NaCl] (up to 3 M maximum) were then
applied, and each elution was collected for subsequent
protein analysis. 10% of each elution was prepared in
SDS sample buffer with 5% b-mercaptoethanol, boiled,
and applied to a 4%-20% gradient SDS-PAGE gel for
electrophoresis. Gels were silver-stained (Pierce) and
photographed.
Duolink assays
The specific interaction between CCL21 and CCR7 was
determined using a proximity ligation assay (PLA;
Duolink, Olink Bioscience) following manufacturer
instructions with the following primary antibodies used:
anti-CCL21 (R&D, MAB3661, 1:100) and anti-CCR7
(Novus, 1:250).
Animal Models and Tumor Metastasis Studies
All animal experiments were reviewed and approved by
the Institutional Animal Care and Use Committee
(IACUC). All mice used in the studies were between
four to eight weeks of age. Mutant Ndst1
f/fTekCre+a n d
Ndst1
f/fTekCre- littermate control mice on the C57Bl/6
background were generated as previously described [37].
Mutant Ndst1
f/fProx1
+/CreERT2 mice (and Ndst1
f/fProx1
-/
CreERT2 control littermates) were generated through
breeding of the Prox1
+/CreERT2 construct (generously
provided by Dr. Guillermo Oliver at St. Jude Children’s
Research Hospital, Memphis, TN) [43] with Ndst1
f/f
conditional mutants (first described in [37]), following
extensive backcrossing of both lines onto the C57Bl/6
background. To evaluate the activity of Cre recombi-
nase, Prox1
+/CreERT2 mice were also bred to Rosa26R
reporter mice (Jackson Laboratory). To induce Cre
recombinase activity, tamoxifen (Sigma) dissolved in
corn oil was intraperitoneally (i.p.) injected into all mice
(i.e., both Prox1
+/CreERT2 and Prox1
-/CreERT2 controls) at
0.12 mg/g body weight for five consecutive days. All
mice were maintained in a pathogen-free facility on a
12 h:12 h ligh-dark cycle with food and water provided
ad libitum. To investigate metastasis of tumor cells to
regional lymph node, mice were anaesthetized with iso-
flurane gas vapor and 2.5 × 10
5 LLC were subcutaneously
(s.c.) injected into a skin fold in the caudal-medal aspect
of the inguinal region. For experimental mice (under-
going tamoxifen injection), LLC tumor cells were admi-
nistered on Day 7 following the last injection of
tamoxifen. Fourteen days after LLC injection, mice were
sacrificed with both primary tumor and left subiliac LN
isolated. The length (L) and width (W) of the primary
tumor were measured with caliper and the tumor size
was calculated as 0.5 × L × W
2. (During this time period
for growth, injection of GFP-expressing LLC tumor cells
resulted in subcutaneous tumors that grew to ~0.5 cm
diameter, and were comparable in both mutant and wild-
type mice. Larger tumors were avoided in the TekCre
model, given known effects of the mutation on the sub-
cutaneous growth and vascularization of larger LLC
tumors [25].) Isolated tissues were fixed in 10% buffered
neutral formalin (Fisher) at room temperature for 24 h.
Purification of LEC from Ndst1
f/fTekCre
+ mutant mice
(and Cre
- wildtype littermates) for analyses of Ndst1
expression were carried out using LEC isolated from
two tissue sources: (1) LEC isolation from freshly
resected mouse lungs, wherein lungs were washed,
digested in 0.2% collagenase (Sigma) following mechani-
cal disruption with scissors, strained (40 μms t r a i n e r )
for cell enrichment, labeled with biotinylated antibody
to mouse LYVE-1, and purified into culture (EBM-2
growth medium; Lonza) using anti-biotin magnetic
beads according to manufacturer (Miltenyi) instructions;
(2) LEC isolated from lymphatic proliferative lesions
(abdominal oil granuloma/lymphangioma lesions) fol-
lowing the method of Mancardi and others [57].
Whole-mount LacZ staining
Whole-mount lacZ staining was performed as previously
described [58]. Briefly, LN and other tissues were freshly
isolated, fixed in b-galactosidase fixative (0.2% glutaralde-
hyde, 5 mM EDTA and 2 mM MgCl2 in PBS) at room
temperature for 2 h, washed three times (30 min each
wash) in b-galactosidase wash buffer (0.01% sodium
deoxycholate, 0.02% NP-40 and 2 mM MgCl2 in PBS),
and stained overnight in b-galactosidase staining solution
(1 mg/mL X-gal, 5 mM K4Fe(CN)6 and 5 mM K3Fe(CN)
6 in b-galactosidase wash buffer) at room temperature
with gentle rocking. For histological examination, stained
tissues were washed three times in PBS and post-fixed in
10% buffered neutral formalin at 4°C overnight,
embedded into paraffin and 5-μm sections were cut.
Immunohistochemistry
Formalin-fixed tissues were embedded into paraffin and
5-μm thick sections were made. Following depraffinization
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section slides were cooked in antigen retrieval buffer
(10 mM sodium citrate, pH 6.0) under high pressure for
10 min. The endogenous peroxidase activity was blocked
with 3% hydrogen peroxide in dH2O for 10 min and the
endogenous biotin blocked with Avidin-Biotin kit (Vector
Lab) based on manufacturer instructions. A third blocking
with 5% normal horse serum in TBST was performed at
room temperature for 1 h. Tissue sections were then incu-
bated with primary antibody at 4°C overnight. The follow-
ing antibodies were used: a-LYVE1 (1:2000, R&D), a-
CCL21 (1:2000, R&D), a-pan-keratin (1:5000, Cell Signal-
ing). All antibodies were tested for conferring specific
staining with isotype-matched IgG as negative control in
preliminary experiments. Then the tissue sections were
stained with a biotinylated secondary antibody (1:1000,
Vector Lab) with the signal amplified and developed using
Vectastain ABC kit followed by either DAB or Vector Blue
substrate (Vector Lab). To quantify the pan-keratin and
CCL21 signals within the lymph node, two sections sepa-
rated by 100 μm were imaged under 40× magnification.
The positive signals were quantified using NIH image J
software and averaged to represent the signal within each
lymph node.
Heparin binding ELISA
Heparin-binding ELISA was performed using a heparan
sulfate binding plate (BD Biosciences) following the
manufacturer’s instructions. Briefly, the 96-well plate
was coated with 25 μg/mL porcine intestinal heparan
sulfate (Sigma) in PBS overnight at room temperature.
After washing with PBS containing 0.05% (v/v) Tween
20 and blocking with 0.2% (w/v) gelatin in PBS, wells
were incubated for 2 h with recombinant human
CCL21 (Peprotech) serially diluted in PBS. Wells were
then washed, and biotinylated anti-CCL21 polyclonal
antibody was added at 200 ng/mL in blocking buffer.
After washing, Streptavidin-HRP (R&D) was added
(1:200 in blocking buffer for 30 min) followed by PBS
wash. Tween, substrate solution (1:1 H2O2 :t e t r a -
methylbenzidine) was added and absorbances were
read at O.D. 650 nm after 10-min incubation at room
temperature.
Statistical analyses
Quantitative data were presented as mean ± SD for
three replicates or independent experiments. Signifi-
cance between groups was calculated with two-tailed
Student’s t test. Difference of lymph node metastasis
between Ndst1
f/fTekCre+a n dNdst1
f/fTekCre-o r
between Ndst1
f/fProx1
+/CreERT2 and Ndst1
f/fProx1
-/CreERT2
mice was performed using the Rank Order test. A value
of P < 0.05 was considered statistically significant.
Additional material
Additional file 1: Figure S1: siRNA transfection knocks down the
expression of HS biosynthetic enzymes but not CCL21 or CCR7 in
human lymphatic endothelia. A. Primary human lymphatic endothelial
cells (hLEC) were transfected with either control RNA (siDS), siNdst1 or
siXylT2. The steady-state mRNA levels of Ndst1, XylT2, CCL21 or CCR7
were examined by RT-qPCR and indexed to that of b-actin. The target/b-
actin expression ratio in siDS-transfected hLEC was arbitrarily defined as
1. B. hLEC were transfected with either control scrambled-duplex RNA
(siDS) or siNdst1. The protein level of Ndst1 was determined by Western
immunoblot. Tubulin was measured as a loading control.
Additional file 2: Figure S2: siNdst1 transfection alters the sulfation
status of lymphatic-secreted heparan sulfate. HS was purified from
the conditioned medium of hLEÇ transfected with control scrambled-
duplex RNA (siDS) or siNdst1, and the sulfation status was examined by
disaccharide analysis using liquid chromatography/mass spectrometry.
Disaccharides listed below axis are named according to published
nomenclature (reference #55 from main REFERENCES section).
Additional file 3: Figure S3: CCL21 binding to plate-immobilized
heparin: Increasing concentrations of recombinant human CCL21 were
exposed to porcine intestinal HS pre-bound to an HS-binding plate,
followed by washing and measurement of bound chemokine through
ELISA to assess solid-phase binding of the chemokine to plate-
immobilized glycan. (Estimated Kd ~ 100 ng/ml or approximately 8.3
nM.)
Additional file 4: Figure S4: CCR7 is expressed on human lymphatic
endothelial cells: A. The expression of CCR7 on the surface of hLEC was
detected using anti-CCR7 antibody (green, left panel) by
immunofluorescence. As a negative control, isotype-matched IgG (green,
right panel) was used. The nuclei were stained with DAPI (blue). Images
were taken under 100× magnification. Scale bar, 100 μm. B. Lysates from
cultured hLEC were assayed for CCR7 expression by Western
immunoblot (right lane), with expression in cultured LLC tumor cells (left
lane) as a reference, and b-actin expression shown below as a loading
control.
Additional file 5: Figure S5: Lymphatic vascular proliferation in
lymph nodes of tumor-bearing mutant mice: Lymphatic vascular
density was plotted for Ndst1f/f Prox1+/CreERT2 mutant mice versus that
of Cre-negative control littermates by quantifying LYVE-1 signal per
lymph node (LN) (in arbitrary signal/LN units, shown in scatter-plot on
the left). Graph on the right shows mean values (+/-SD) for an
experiment examining N = 6 mutants versus N = 5 control mice. P =
0.14 for the difference in mean values.
Additional file 6: Figure S6: Immunolocalization of CCL21 and LYVE-
1 in regional lymph nodes from tumor-bearing mice: Lymph node
sections from wildtype LLC tumor-bearing mice were immuno-stained
with LYVE-1 (brown) and CCL21 (blue). Numerous CCL21+ cells (which
co-localized with pan-keratin positive tumor deposits; see Figure 7D)
were found in lymphatic-vascular rich regions of the lymph node. In
addition, in some regions of lymphatic vessles, areas of co-localization of
CCL21 with LYVE-1 (pink arrows) were noted (Bar = 50 μm).
Additional file 7: Figure S7: Spectrum of major heparan sulfate
proteoglycan core proteins expressed by human lymphatic
endothelial cells: The steady-state mRNA levels of indicated HS
proteoglycan core proteins were examined in hLEC by RT-qPCR and
presented as percentage expression relative to that of b-actin. Plot shows
secreted as well as cell-surface bound core proteins.
Additional file 8: Table S1: Primer Sequences (Forward/Reverse)
used for Quantitative PCR. of major human HS core proteins expressed
by primary human lymphatic endothelial cells.
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